Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Biological: MEDI-522

First Posted Date: 2005-05-25

Last Posted Date: 2012-03-14

Lead Sponsor: MedImmune LLC

Target Recruit Count: 18

Registration Number: NCT00111696

Locations: 🇺🇸
University Of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: CAIV-T
Other: TIV

First Posted Date: 2005-05-24

Last Posted Date: 2008-07-24

Lead Sponsor: MedImmune LLC

Target Recruit Count: 52

Registration Number: NCT00111579

Locations: 🇺🇸
Wee Care Pediatrics, Layton, Utah, United States
🇺🇸
Bear Care Pediatrics, Ogden, Utah, United States
🇺🇸
Alpine Pediatrics, Pleasant Grove, Utah, United States

and more 2 locations

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Phase 1

Terminated

Conditions: Lymphoma
Leukemia
Cancer

First Posted Date: 2005-03-14

Last Posted Date: 2007-06-14

Lead Sponsor: MedImmune LLC

Target Recruit Count: 80

Registration Number: NCT00105313

Locations: 🇺🇸
USC/Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

and more 8 locations

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Idarubincin and Amufostine (Ethyol)
Drug: Idarubincin

First Posted Date: 2004-06-25

Last Posted Date: 2009-01-29

Lead Sponsor: MedImmune LLC

Target Recruit Count: 54

Registration Number: NCT00086099

Locations: 🇺🇸
Scripps Cancer Center, San Diego, California, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Cancer Care Center, New Albany, Indiana, United States

and more 16 locations

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Esophagitis
Pneumonitis
Non-Small Cell Lung Carcinoma

First Posted Date: 2004-04-09

Last Posted Date: 2007-08-21

Lead Sponsor: MedImmune LLC

Target Recruit Count: 130

Registration Number: NCT00081315

Locations: 🇺🇸
Cedars Sanai, Los Angeles, California, United States
🇺🇸
Radiation Oncology Center, Sacramento, California, United States
🇺🇸
The Center for Cancer Care, Torrington, Connecticut, United States

and more 21 locations

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase 1

Suspended

Conditions: Leukemia
Lymphoma

Interventions: Drug: BL22 immunotoxin
Procedure: antibody-drug conjugate therapy
Procedure: immunotoxin therapy
Procedure: monoclonal antibody therapy

First Posted Date: 2004-02-12

Last Posted Date: 2007-12-28

Lead Sponsor: MedImmune LLC

Target Recruit Count: 95

Registration Number: NCT00077493

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: BL22

First Posted Date: 2003-12-11

Last Posted Date: 2010-06-22

Lead Sponsor: MedImmune LLC

Target Recruit Count: 36

Registration Number: NCT00074048

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: MEDI-522
Biological: Docetaxel + Prednisone* + Zoledronic Acid

First Posted Date: 2003-11-17

Last Posted Date: 2008-01-15

Lead Sponsor: MedImmune LLC

Target Recruit Count: 150

Registration Number: NCT00072930

Locations: 🇺🇸
Clinical Research Consultants, Inc., Hoover, Alabama, United States
🇺🇸
Highlands Oncology Group, P.A., Springdale, Arizona, United States
🇺🇸
Arizona Hematology-Oncology, P.C., Tucson, Arizona, United States

and more 54 locations

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: MEDI-522
Other: Placebo

First Posted Date: 2003-09-17

Last Posted Date: 2007-11-27

Lead Sponsor: MedImmune LLC

Target Recruit Count: 300

Registration Number: NCT00069017

Locations: 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Sun Valley Arthritis Center, Glendale, Arizona, United States
🇺🇸
Arizona Research & Education, Phoenix, Arizona, United States

and more 37 locations

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma
Malignant Metastatic Melanoma

Interventions: Biological: Integrin + Dacarbazine
Biological: MEDI--522

First Posted Date: 2003-08-07

Last Posted Date: 2008-01-15

Lead Sponsor: MedImmune LLC

Target Recruit Count: 110

Registration Number: NCT00066196

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸
Saint Francis Memorial Hospital, San Francisco, California, United States

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy